{"id": "article-145910_0", "title": "Antiphospholipid Antibody Testing -- Introduction", "content": "Antiphospholipid testing is part of the diagnostic workup for possible underlying autoimmune conditions in patients presenting with arterial, venous, and microvascular thrombosis, along with gestational or obstetric complications and morbidity. [1] [2] [3] This testing includes\u00a03 main antibody classifications: Lupus anticoagulants (IgG, IgM) Anticardiolipin antibodies (IgA, IgG, and IgM) Anti-\u03b22-glycoprotein Ib (anti-\u03b22GPIb) antibodies (IgA, IgG, and IgM)", "contents": "Antiphospholipid Antibody Testing -- Introduction. Antiphospholipid testing is part of the diagnostic workup for possible underlying autoimmune conditions in patients presenting with arterial, venous, and microvascular thrombosis, along with gestational or obstetric complications and morbidity. [1] [2] [3] This testing includes\u00a03 main antibody classifications: Lupus anticoagulants (IgG, IgM) Anticardiolipin antibodies (IgA, IgG, and IgM) Anti-\u03b22-glycoprotein Ib (anti-\u03b22GPIb) antibodies (IgA, IgG, and IgM)"}
{"id": "article-145910_1", "title": "Antiphospholipid Antibody Testing -- Introduction", "content": "These antibodies\u00a0should be tested together to assess the risk profile for high-risk patients for antiphospholipid syndrome. [4] [5] Incomplete antiphospholipid diagnostic testing could lead to improper diagnosis of antiphospholipid syndrome and could impose catastrophic consequences without intervention. [6] [7] [8]", "contents": "Antiphospholipid Antibody Testing -- Introduction. These antibodies\u00a0should be tested together to assess the risk profile for high-risk patients for antiphospholipid syndrome. [4] [5] Incomplete antiphospholipid diagnostic testing could lead to improper diagnosis of antiphospholipid syndrome and could impose catastrophic consequences without intervention. [6] [7] [8]"}
{"id": "article-145910_2", "title": "Antiphospholipid Antibody Testing -- Introduction", "content": "Lupus anticoagulant refers to a diverse antibody group directed against phospholipids and phospholipid-binding proteins, which prolong certain coagulation testing in vitro and cause thrombosis in vivo. Lupus anticoagulant detection involves assessing its effect on various anticoagulation tests, and no single assay measures all the different\u00a0lupus anticoagulant antibodies. Therefore, at least 2 different confirmatory tests are required to establish a positive\u00a0lupus anticoagulant test. Lupus anticoagulant is considered the most predictive test for thrombosis among antibody tests when positive. [9] [10]", "contents": "Antiphospholipid Antibody Testing -- Introduction. Lupus anticoagulant refers to a diverse antibody group directed against phospholipids and phospholipid-binding proteins, which prolong certain coagulation testing in vitro and cause thrombosis in vivo. Lupus anticoagulant detection involves assessing its effect on various anticoagulation tests, and no single assay measures all the different\u00a0lupus anticoagulant antibodies. Therefore, at least 2 different confirmatory tests are required to establish a positive\u00a0lupus anticoagulant test. Lupus anticoagulant is considered the most predictive test for thrombosis among antibody tests when positive. [9] [10]"}
{"id": "article-145910_3", "title": "Antiphospholipid Antibody Testing -- Introduction", "content": "Cardiolipin is an inner mitochondrial membrane component comprising about 20% of the total lipid composition. Anticardiolipin binding to phospholipid anions causes platelet activation. Anticardiolipin antibodies are considered more sensitive but less specific compared to\u00a0lupus\u00a0anticoagulants for predicting thrombosis.", "contents": "Antiphospholipid Antibody Testing -- Introduction. Cardiolipin is an inner mitochondrial membrane component comprising about 20% of the total lipid composition. Anticardiolipin binding to phospholipid anions causes platelet activation. Anticardiolipin antibodies are considered more sensitive but less specific compared to\u00a0lupus\u00a0anticoagulants for predicting thrombosis."}
{"id": "article-145910_4", "title": "Antiphospholipid Antibody Testing -- Introduction", "content": "Anti-\u03b22GPIb antibodies bind to platelets at the\u00a0apoER2\u2032 and glycoprotein Ib-\u03b1 receptors, activating the platelet signaling pathway involving\u00a0MAPK phosphorylation, GP IIb/IIIa conformational change, P-selectin expression, and thromboxane B2 production. [11]", "contents": "Antiphospholipid Antibody Testing -- Introduction. Anti-\u03b22GPIb antibodies bind to platelets at the\u00a0apoER2\u2032 and glycoprotein Ib-\u03b1 receptors, activating the platelet signaling pathway involving\u00a0MAPK phosphorylation, GP IIb/IIIa conformational change, P-selectin expression, and thromboxane B2 production. [11]"}
{"id": "article-145910_5", "title": "Antiphospholipid Antibody Testing -- Etiology and Epidemiology", "content": "According to the revised Sapporo criteria, the diagnosis of persistent positive antiphospholipids is established when antiphospholipid antibodies are detected on 2 or more occasions at least 12 weeks apart. [12] This condition could indicate underlying antiphospholipid syndrome, a systemic autoimmune disease, clinically characterized by thrombotic or pregnancy\u00a0or obstetric events. Antiphospholipid syndrome is classified as primary if not related to other underlying autoimmune diseases. On the other hand, secondary antiphospholipid syndrome is associated with systemic autoimmune diseases,\u00a0with systemic lupus erythematosus as\u00a0a common association. [6] [8] In a population-based study, the estimated incidence and prevalence of antiphospholipid syndrome determined were 2.1 per 100,000 population per year and 50 per 100,000 population, respectively. [13] Triple positivity, which is defined as positivity for lupus anticoagulants, anticardiolipin antibodies, and anti-\u03b22GPIb, is associated with greatly increased risks for thrombosis, especially with autoimmune diseases, including for a first-event thrombosis in asymptomatic carriers. [5] [14]", "contents": "Antiphospholipid Antibody Testing -- Etiology and Epidemiology. According to the revised Sapporo criteria, the diagnosis of persistent positive antiphospholipids is established when antiphospholipid antibodies are detected on 2 or more occasions at least 12 weeks apart. [12] This condition could indicate underlying antiphospholipid syndrome, a systemic autoimmune disease, clinically characterized by thrombotic or pregnancy\u00a0or obstetric events. Antiphospholipid syndrome is classified as primary if not related to other underlying autoimmune diseases. On the other hand, secondary antiphospholipid syndrome is associated with systemic autoimmune diseases,\u00a0with systemic lupus erythematosus as\u00a0a common association. [6] [8] In a population-based study, the estimated incidence and prevalence of antiphospholipid syndrome determined were 2.1 per 100,000 population per year and 50 per 100,000 population, respectively. [13] Triple positivity, which is defined as positivity for lupus anticoagulants, anticardiolipin antibodies, and anti-\u03b22GPIb, is associated with greatly increased risks for thrombosis, especially with autoimmune diseases, including for a first-event thrombosis in asymptomatic carriers. [5] [14]"}
{"id": "article-145910_6", "title": "Antiphospholipid Antibody Testing -- Specimen Requirements and Procedure", "content": "The preanalytical stage for testing antiphospholipid antibodies requires careful handling to prevent sample activation, loss of coagulant proteins, and contamination. [15] Blood samples, whether in serum or citrate-anticoagulated plasma form, are required. Plasma should be platelet-poor (<1000/L), preferably using the double centrifugation technique. [16] Frozen plasma should be stored at \u221270 \u00b0C to maintain integrity, avoiding repeated freezing and thawing. Thawing should occur at 37 \u00b0C for 5 minutes\u00a0in a water bath by total immersion and then mixed before testing. Samples can be stored at 2 to 8 \u00b0C for 2 to 3 days or at \u221220 \u00b0C or below for longer periods. [17] Adherence to these guidelines ensures result accuracy and minimizes pre-analytical errors.", "contents": "Antiphospholipid Antibody Testing -- Specimen Requirements and Procedure. The preanalytical stage for testing antiphospholipid antibodies requires careful handling to prevent sample activation, loss of coagulant proteins, and contamination. [15] Blood samples, whether in serum or citrate-anticoagulated plasma form, are required. Plasma should be platelet-poor (<1000/L), preferably using the double centrifugation technique. [16] Frozen plasma should be stored at \u221270 \u00b0C to maintain integrity, avoiding repeated freezing and thawing. Thawing should occur at 37 \u00b0C for 5 minutes\u00a0in a water bath by total immersion and then mixed before testing. Samples can be stored at 2 to 8 \u00b0C for 2 to 3 days or at \u221220 \u00b0C or below for longer periods. [17] Adherence to these guidelines ensures result accuracy and minimizes pre-analytical errors."}
{"id": "article-145910_7", "title": "Antiphospholipid Antibody Testing -- Diagnostic Tests", "content": "Antiphospholipid antibodies are a family of autoantibodies that can interact with negatively charged phospholipids and phospholipid-binding proteins. [18] [19] Specifically, these antibodies inhibit in vitro\u00a0coagulation resulting from antiphospholipid binding to plasma proteins, mainly \u03b22-glycoprotein or prothrombin, with an affinity for phospholipids. Lupus anticoagulant is a semantic paradox, as these antibodies\u00a0are associated with clinical thrombosis. In contrast, an anticoagulant effect is observed in the laboratory or in vitro as a prolongation of clotting times. [5] [20] Moreover, lupus anticoagulants and other antiphospholipid antibody tests are included in the Classification Criteria for Systemic Lupus Erythematosus as part of the immunologic domain but are not the sole criteria. [21] Of note, testing should be performed when a patient is clinically stable and not during an acute event, as acute thrombosis can cause inaccurate testing and can even cause transiently elevated anticardiolipin antibodies. [2] For an overview of\u00a0lupus anticoagulants and other anticoagulants on various testing parameters, please see Table. Effect of Lupus Anticoagulant and Anticoagulants on Laboratory Testing.", "contents": "Antiphospholipid Antibody Testing -- Diagnostic Tests. Antiphospholipid antibodies are a family of autoantibodies that can interact with negatively charged phospholipids and phospholipid-binding proteins. [18] [19] Specifically, these antibodies inhibit in vitro\u00a0coagulation resulting from antiphospholipid binding to plasma proteins, mainly \u03b22-glycoprotein or prothrombin, with an affinity for phospholipids. Lupus anticoagulant is a semantic paradox, as these antibodies\u00a0are associated with clinical thrombosis. In contrast, an anticoagulant effect is observed in the laboratory or in vitro as a prolongation of clotting times. [5] [20] Moreover, lupus anticoagulants and other antiphospholipid antibody tests are included in the Classification Criteria for Systemic Lupus Erythematosus as part of the immunologic domain but are not the sole criteria. [21] Of note, testing should be performed when a patient is clinically stable and not during an acute event, as acute thrombosis can cause inaccurate testing and can even cause transiently elevated anticardiolipin antibodies. [2] For an overview of\u00a0lupus anticoagulants and other anticoagulants on various testing parameters, please see Table. Effect of Lupus Anticoagulant and Anticoagulants on Laboratory Testing."}
{"id": "article-145910_8", "title": "Antiphospholipid Antibody Testing -- Diagnostic Tests", "content": "The laboratory diagnosis\u00a0of antiphospholipid antibodies typically employs 2 main categories of screening methods: Immunological assays (anticardiolipin and anti-\u03b22GPIb) Clot-based assays, which\u00a0include incorporating phospholipids into the reagent system and evaluating clotting time, are utilized to detect various lupus anticoagulant antibodies) [22]", "contents": "Antiphospholipid Antibody Testing -- Diagnostic Tests. The laboratory diagnosis\u00a0of antiphospholipid antibodies typically employs 2 main categories of screening methods: Immunological assays (anticardiolipin and anti-\u03b22GPIb) Clot-based assays, which\u00a0include incorporating phospholipids into the reagent system and evaluating clotting time, are utilized to detect various lupus anticoagulant antibodies) [22]"}
{"id": "article-145910_9", "title": "Antiphospholipid Antibody Testing -- Diagnostic Tests -- Immunological Assays", "content": "Enzyme-linked immunosorbent assay (ELISA) technique is commonly employed to detect\u00a0anticardiolipin and anti-\u03b22GPIb. In this method, the solid phase is coated with cardiolipin and \u03b22 GPI as cofactors. The ELISA method detects IgM, IgG, and IgA classes of anticardiolipin antibodies. [5] An important point is that lupus anticoagulants and anticardiolipin antibodies differ in their phospholipid-binding characteristics; hence, the detection of anticardiolipin antibodies is not specific for the presence of lupus anticoagulants, although they may be present in the same patient. [23] Anti-\u03b22GPIb antibodies also utilize the ELISA technique. Both of these antibodies are primarily IgG and IgM; IgA antibodies have been isolated and are associated with increased thrombosis, but the IgA antibodies are\u00a0typically associated with IgG and IgM. [24]", "contents": "Antiphospholipid Antibody Testing -- Diagnostic Tests -- Immunological Assays. Enzyme-linked immunosorbent assay (ELISA) technique is commonly employed to detect\u00a0anticardiolipin and anti-\u03b22GPIb. In this method, the solid phase is coated with cardiolipin and \u03b22 GPI as cofactors. The ELISA method detects IgM, IgG, and IgA classes of anticardiolipin antibodies. [5] An important point is that lupus anticoagulants and anticardiolipin antibodies differ in their phospholipid-binding characteristics; hence, the detection of anticardiolipin antibodies is not specific for the presence of lupus anticoagulants, although they may be present in the same patient. [23] Anti-\u03b22GPIb antibodies also utilize the ELISA technique. Both of these antibodies are primarily IgG and IgM; IgA antibodies have been isolated and are associated with increased thrombosis, but the IgA antibodies are\u00a0typically associated with IgG and IgM. [24]"}
{"id": "article-145910_10", "title": "Antiphospholipid Antibody Testing -- Diagnostic Tests -- Clot-Based Assays", "content": "Lupus anticoagulant testing is a multi-step process. The initial screening test uses reagents with a low phospholipid quantity, followed by the same test with a high phospholipid quantity to show that the test prolongation is phospholipid-dependent (and not clotting factor-dependent). The dilute Russell viper venom time (dRVVT) and activated partial thromboplastin time  (APTT)  are the most commonly used tests. [9]", "contents": "Antiphospholipid Antibody Testing -- Diagnostic Tests -- Clot-Based Assays. Lupus anticoagulant testing is a multi-step process. The initial screening test uses reagents with a low phospholipid quantity, followed by the same test with a high phospholipid quantity to show that the test prolongation is phospholipid-dependent (and not clotting factor-dependent). The dilute Russell viper venom time (dRVVT) and activated partial thromboplastin time  (APTT)  are the most commonly used tests. [9]"}
{"id": "article-145910_11", "title": "Antiphospholipid Antibody Testing -- Diagnostic Tests -- Clot-Based Assays", "content": "Dilute Russell viper venom time: The dRVVT is widely regarded as the preferred test for screening and confirmation of lupus anticoagulant. dRVVT\u00a0is more sensitive and specific compared to other global tests. Importantly, it is\u00a0also not affected by factor VIII or IX inhibitors. The dRVVT\u00a0test comprises a screening reagent containing a limited amount of phospholipids with Russell viper venom and a confirmatory reagent containing additional phospholipids with the same amount of Russell viper venom to confirm the presence of phospholipid-dependent lupus anticoagulant. Russell viper venom bypasses factor VII of the extrinsic pathway and the contact and antihemophilic factors of the intrinsic pathway. [9] [25]", "contents": "Antiphospholipid Antibody Testing -- Diagnostic Tests -- Clot-Based Assays. Dilute Russell viper venom time: The dRVVT is widely regarded as the preferred test for screening and confirmation of lupus anticoagulant. dRVVT\u00a0is more sensitive and specific compared to other global tests. Importantly, it is\u00a0also not affected by factor VIII or IX inhibitors. The dRVVT\u00a0test comprises a screening reagent containing a limited amount of phospholipids with Russell viper venom and a confirmatory reagent containing additional phospholipids with the same amount of Russell viper venom to confirm the presence of phospholipid-dependent lupus anticoagulant. Russell viper venom bypasses factor VII of the extrinsic pathway and the contact and antihemophilic factors of the intrinsic pathway. [9] [25]"}
{"id": "article-145910_12", "title": "Antiphospholipid Antibody Testing -- Diagnostic Tests -- Clot-Based Assays", "content": "In normal plasma, in the absence of lupus anticoagulants, factors V and X are directly activated by Russell viper venom, which in the presence of phospholipid and calcium ions, leads to clot formation.\u00a0In patients with lupus anticoagulant, autoantibodies bind to the epitopes of the reagent phospholipids, thereby preventing the activation of the prothrombinase complex.  As a result, the clotting time when using screening reagents in laboratory tests is prolonged. [26]", "contents": "Antiphospholipid Antibody Testing -- Diagnostic Tests -- Clot-Based Assays. In normal plasma, in the absence of lupus anticoagulants, factors V and X are directly activated by Russell viper venom, which in the presence of phospholipid and calcium ions, leads to clot formation.\u00a0In patients with lupus anticoagulant, autoantibodies bind to the epitopes of the reagent phospholipids, thereby preventing the activation of the prothrombinase complex.  As a result, the clotting time when using screening reagents in laboratory tests is prolonged. [26]"}
{"id": "article-145910_13", "title": "Antiphospholipid Antibody Testing -- Diagnostic Tests -- Clot-Based Assays", "content": "Activated partial thromboplastin time: As\u00a0lupus anticoagulants bind to the phospholipid complex, they prolong phospholipid-based coagulation assays. Logically, the APTT is prolonged, and this property has been used to detect lupus anticoagulants. [27] In the context of lupus anticoagulant detection, the APTT test has certain limitations as follows: An important variable related to the suitability of APTT reagents in detecting lupus anticoagulants is the composition of phospholipids used in the reagent system. Different reagents have varying sensitivity for the presence of lupus anticoagulants based on their phospholipid composition. [28]", "contents": "Antiphospholipid Antibody Testing -- Diagnostic Tests -- Clot-Based Assays. Activated partial thromboplastin time: As\u00a0lupus anticoagulants bind to the phospholipid complex, they prolong phospholipid-based coagulation assays. Logically, the APTT is prolonged, and this property has been used to detect lupus anticoagulants. [27] In the context of lupus anticoagulant detection, the APTT test has certain limitations as follows: An important variable related to the suitability of APTT reagents in detecting lupus anticoagulants is the composition of phospholipids used in the reagent system. Different reagents have varying sensitivity for the presence of lupus anticoagulants based on their phospholipid composition. [28]"}
{"id": "article-145910_14", "title": "Antiphospholipid Antibody Testing -- Diagnostic Tests -- Clot-Based Assays", "content": "The APTT test is affected by the presence of factor VIII, IX, and XI inhibitors. [29] Mixing studies are performed to rule out a lack of clotting factors as a cause of APTT prolongation. A 1:1 or 1:4 (normal plasma to patient plasma) is used in mixing studies. Failure to correct the prolongation of clotting time using the mixing studies indicates the presence of lupus anticoagulants. [30]", "contents": "Antiphospholipid Antibody Testing -- Diagnostic Tests -- Clot-Based Assays. The APTT test is affected by the presence of factor VIII, IX, and XI inhibitors. [29] Mixing studies are performed to rule out a lack of clotting factors as a cause of APTT prolongation. A 1:1 or 1:4 (normal plasma to patient plasma) is used in mixing studies. Failure to correct the prolongation of clotting time using the mixing studies indicates the presence of lupus anticoagulants. [30]"}
{"id": "article-145910_15", "title": "Antiphospholipid Antibody Testing -- Diagnostic Tests -- Clot-Based Assays", "content": "The APTT test is also used to monitor heparin therapy. However, the test's ability to specifically detect lupus anticoagulant is reduced. [31] The presence of heparin can be ruled out using a thrombin time test.\u00a0If the thrombin time is normal, then heparin is likely not present. However, if the thrombin time is abnormal, it could be due to heparin. In this case, a heparin neutralization test can be used to confirm the presence of heparin.\u00a0In this test, various concentrations of protamine sulfate are added to plasma before the addition of the thrombin reagent. When protamine sulfate neutralizes all the heparin present, the clotting time reverts to normal value. [32]", "contents": "Antiphospholipid Antibody Testing -- Diagnostic Tests -- Clot-Based Assays. The APTT test is also used to monitor heparin therapy. However, the test's ability to specifically detect lupus anticoagulant is reduced. [31] The presence of heparin can be ruled out using a thrombin time test.\u00a0If the thrombin time is normal, then heparin is likely not present. However, if the thrombin time is abnormal, it could be due to heparin. In this case, a heparin neutralization test can be used to confirm the presence of heparin.\u00a0In this test, various concentrations of protamine sulfate are added to plasma before the addition of the thrombin reagent. When protamine sulfate neutralizes all the heparin present, the clotting time reverts to normal value. [32]"}
{"id": "article-145910_16", "title": "Antiphospholipid Antibody Testing -- Diagnostic Tests -- Clot-Based Assays", "content": "Tissue thromboplastin inhibition test :\u00a0The tissue thromboplastin inhibition (TTI) test, also known as the dilute prothrombin time (dPT) test, utilizes a diluted thromboplastin reagent.\u00a0In this test, the thromboplastin reagent is diluted 1:50 or 1:500 with saline, and the results are expressed as the ratio of patient values to normal control values. [33] The TTI test is affected by numerous variables: Species and tissue origin of thromboplastin can affect the test results as different sources have varying sensitivity and responsiveness.\u00a0Rabbit brain thromboplastin, conventionally utilized in the TTI test, is highly sensitive to lupus anticoagulant. However, it is susceptible to inter-laboratory variability due to natural discrepancies in the composition of the rabbit brain. [34]", "contents": "Antiphospholipid Antibody Testing -- Diagnostic Tests -- Clot-Based Assays. Tissue thromboplastin inhibition test :\u00a0The tissue thromboplastin inhibition (TTI) test, also known as the dilute prothrombin time (dPT) test, utilizes a diluted thromboplastin reagent.\u00a0In this test, the thromboplastin reagent is diluted 1:50 or 1:500 with saline, and the results are expressed as the ratio of patient values to normal control values. [33] The TTI test is affected by numerous variables: Species and tissue origin of thromboplastin can affect the test results as different sources have varying sensitivity and responsiveness.\u00a0Rabbit brain thromboplastin, conventionally utilized in the TTI test, is highly sensitive to lupus anticoagulant. However, it is susceptible to inter-laboratory variability due to natural discrepancies in the composition of the rabbit brain. [34]"}
{"id": "article-145910_17", "title": "Antiphospholipid Antibody Testing -- Diagnostic Tests -- Clot-Based Assays", "content": "The choice of normal reference plasma is the most critical variable because, depending on the laboratory, the choice of reference plasma could be lyophilized plasma, a frozen plasma pool, or fresh plasma. Therefore, the patient-to-normal ratio can change according to the choice of normal plasma.\u00a0To reduce variability, laboratories should develop standardized protocols for selecting and handling reference plasma. [35] Some IgM lupus anticoagulants do not prolong the TTI test. [36]", "contents": "Antiphospholipid Antibody Testing -- Diagnostic Tests -- Clot-Based Assays. The choice of normal reference plasma is the most critical variable because, depending on the laboratory, the choice of reference plasma could be lyophilized plasma, a frozen plasma pool, or fresh plasma. Therefore, the patient-to-normal ratio can change according to the choice of normal plasma.\u00a0To reduce variability, laboratories should develop standardized protocols for selecting and handling reference plasma. [35] Some IgM lupus anticoagulants do not prolong the TTI test. [36]"}
{"id": "article-145910_18", "title": "Antiphospholipid Antibody Testing -- Diagnostic Tests -- Clot-Based Assays", "content": "Kaolin clotting time: Kaolin clotting time (KCT) is similar to APTT, the difference being that the KCT reagent is devoid of phospholipids and incorporates kaolin as a contact activator\u00a0through the intrinsic pathway. [37] The test is performed on a range of normal and patient plasma. Different response patterns are obtained, indicating the presence of lupus anticoagulants or the deficiency of 1 or more coagulation factors. [38] The KCT test, although sensitive, is not specific for detecting lupus anticoagulants. In addition, it has the following limitations: Test automation is challenging, making it more labor-intensive and prone to variability. [39] The test shows prolonged results with factor VIII, IX, XI, and XII deficiency or corresponding inhibitors. [37] The test is also highly sensitive to the presence of heparin. [40]", "contents": "Antiphospholipid Antibody Testing -- Diagnostic Tests -- Clot-Based Assays. Kaolin clotting time: Kaolin clotting time (KCT) is similar to APTT, the difference being that the KCT reagent is devoid of phospholipids and incorporates kaolin as a contact activator\u00a0through the intrinsic pathway. [37] The test is performed on a range of normal and patient plasma. Different response patterns are obtained, indicating the presence of lupus anticoagulants or the deficiency of 1 or more coagulation factors. [38] The KCT test, although sensitive, is not specific for detecting lupus anticoagulants. In addition, it has the following limitations: Test automation is challenging, making it more labor-intensive and prone to variability. [39] The test shows prolonged results with factor VIII, IX, XI, and XII deficiency or corresponding inhibitors. [37] The test is also highly sensitive to the presence of heparin. [40]"}
{"id": "article-145910_19", "title": "Antiphospholipid Antibody Testing -- Diagnostic Tests -- Clot-Based Assays", "content": "Platelet neutralization procedure: The platelet neutralization procedure (PNP) is based on the ability of platelets to correct in vitro coagulation abnormalities significantly. [41] The disrupted platelet membranes in the freeze-thawed platelet suspension neutralize phospholipid antibodies in the plasma of patients with lupus anticoagulant.\u00a0After the patient plasma is mixed with the freeze-thawed platelet suspension, the APTT is shortened compared\u00a0to the original baseline APTT due to increased phospholipid availability and platelet absorption of lupus anticoagulant. However, failure to shorten the clotting time suggests a coagulation factor inhibitor. [42] A correction of the baseline APTT by a defined amount of time,\u00a0typically 3\u00a0to 5 seconds or more,  when platelet suspension is added compared to the control\u00a0suggests the presence of\u00a0lupus anticoagulant. [41] The PNP test, although useful, has not gained wide usage due to the following reasons:", "contents": "Antiphospholipid Antibody Testing -- Diagnostic Tests -- Clot-Based Assays. Platelet neutralization procedure: The platelet neutralization procedure (PNP) is based on the ability of platelets to correct in vitro coagulation abnormalities significantly. [41] The disrupted platelet membranes in the freeze-thawed platelet suspension neutralize phospholipid antibodies in the plasma of patients with lupus anticoagulant.\u00a0After the patient plasma is mixed with the freeze-thawed platelet suspension, the APTT is shortened compared\u00a0to the original baseline APTT due to increased phospholipid availability and platelet absorption of lupus anticoagulant. However, failure to shorten the clotting time suggests a coagulation factor inhibitor. [42] A correction of the baseline APTT by a defined amount of time,\u00a0typically 3\u00a0to 5 seconds or more,  when platelet suspension is added compared to the control\u00a0suggests the presence of\u00a0lupus anticoagulant. [41] The PNP test, although useful, has not gained wide usage due to the following reasons:"}
{"id": "article-145910_20", "title": "Antiphospholipid Antibody Testing -- Diagnostic Tests -- Clot-Based Assays", "content": "Due to limited stability, the platelet preparations lose their activities on storage and hence do not show reproducible results. [19] They cannot differentiate between lupus anticoagulants and factor VIII inhibitors. [17]", "contents": "Antiphospholipid Antibody Testing -- Diagnostic Tests -- Clot-Based Assays. Due to limited stability, the platelet preparations lose their activities on storage and hence do not show reproducible results. [19] They cannot differentiate between lupus anticoagulants and factor VIII inhibitors. [17]"}
{"id": "article-145910_21", "title": "Antiphospholipid Antibody Testing -- Diagnostic Tests -- Clot-Based Assays", "content": "Hexagonal phase phospholipid neutralization: The hexagonal phase neutralization assay is a comprehensive test involving the mixing of patient plasma with normal control plasma and\u00a0subsequent incubation, both with and without hexagonal phase (II) phosphatidylethanolamine (HPE) phospholipid. Subsequently, an APTT analysis is conducted simultaneously on both samples using a lupus anticoagulant-sensitive reagent with a low phospholipid concentration. [43] In cases where\u00a0lupus anticoagulant is present, its activity is neutralized by the HPE, leading to a shorter clotting time compared to the sample incubated without HPE. The inclusion of normal plasma in the patient mixture serves to correct for any potential factor deficiency. If there is no notable reduction in clotting time in the tube containing HPE, it suggests the presence of a specific factor inhibitor rather than a lupus anticoagulant. The test results are typically reported as the variance in clotting time between the tube lacking HPE and the one containing HPE. [44]", "contents": "Antiphospholipid Antibody Testing -- Diagnostic Tests -- Clot-Based Assays. Hexagonal phase phospholipid neutralization: The hexagonal phase neutralization assay is a comprehensive test involving the mixing of patient plasma with normal control plasma and\u00a0subsequent incubation, both with and without hexagonal phase (II) phosphatidylethanolamine (HPE) phospholipid. Subsequently, an APTT analysis is conducted simultaneously on both samples using a lupus anticoagulant-sensitive reagent with a low phospholipid concentration. [43] In cases where\u00a0lupus anticoagulant is present, its activity is neutralized by the HPE, leading to a shorter clotting time compared to the sample incubated without HPE. The inclusion of normal plasma in the patient mixture serves to correct for any potential factor deficiency. If there is no notable reduction in clotting time in the tube containing HPE, it suggests the presence of a specific factor inhibitor rather than a lupus anticoagulant. The test results are typically reported as the variance in clotting time between the tube lacking HPE and the one containing HPE. [44]"}
{"id": "article-145910_22", "title": "Antiphospholipid Antibody Testing -- Diagnostic Tests -- Clot-Based Assays", "content": "Mixing tests: The mixing study is a crucial test used to distinguish between factor deficiencies and inhibitors, such as lupus anticoagulant, in cases of unexplained prolonged clotting times. The test involves mixing equal parts of patient plasma with normal pooled plasma and then evaluating the clotting time of the mixture. If the clotting time corrects, it suggests a factor deficiency; if it does not correct, it suggests the presence of a circulating inhibitor, such as\u00a0lupus anticoagulant or specific factor inhibitors. [45]", "contents": "Antiphospholipid Antibody Testing -- Diagnostic Tests -- Clot-Based Assays. Mixing tests: The mixing study is a crucial test used to distinguish between factor deficiencies and inhibitors, such as lupus anticoagulant, in cases of unexplained prolonged clotting times. The test involves mixing equal parts of patient plasma with normal pooled plasma and then evaluating the clotting time of the mixture. If the clotting time corrects, it suggests a factor deficiency; if it does not correct, it suggests the presence of a circulating inhibitor, such as\u00a0lupus anticoagulant or specific factor inhibitors. [45]"}
{"id": "article-145910_23", "title": "Antiphospholipid Antibody Testing -- Diagnostic Tests -- Clot-Based Assays", "content": "Confirmatory tests: The principle behind employing confirmatory tests for lupus anticoagulants is based on their\u00a0ability to counteract the impact of\u00a0lupus anticoagulant by elevating the phospholipid concentration in the test environment. This counteraction reduces the prolonged coagulation time if attributable to lupus anticoagulant. In contrast, if the prolonged coagulation time results from the presence of an inhibitor targeting one of the coagulation factors, the coagulation time remains prolonged despite the increased phospholipid concentration. [26] [46]", "contents": "Antiphospholipid Antibody Testing -- Diagnostic Tests -- Clot-Based Assays. Confirmatory tests: The principle behind employing confirmatory tests for lupus anticoagulants is based on their\u00a0ability to counteract the impact of\u00a0lupus anticoagulant by elevating the phospholipid concentration in the test environment. This counteraction reduces the prolonged coagulation time if attributable to lupus anticoagulant. In contrast, if the prolonged coagulation time results from the presence of an inhibitor targeting one of the coagulation factors, the coagulation time remains prolonged despite the increased phospholipid concentration. [26] [46]"}
{"id": "article-145910_24", "title": "Antiphospholipid Antibody Testing -- Diagnostic Tests -- Clot-Based Assays", "content": "The results, expressed as a ratio, are further useful in classifying the patient as having normal, moderate, high, and very high levels of lupus anticoagulant.\u00a0Once the diagnosis of the antiphospholipid syndrome is confirmed, repeat testing is not required, although some consider retesting with changes in clinical symptoms.\u00a0If the results of the lupus anticoagulant are borderline, retesting after at least 1 week is suggested. [47]", "contents": "Antiphospholipid Antibody Testing -- Diagnostic Tests -- Clot-Based Assays. The results, expressed as a ratio, are further useful in classifying the patient as having normal, moderate, high, and very high levels of lupus anticoagulant.\u00a0Once the diagnosis of the antiphospholipid syndrome is confirmed, repeat testing is not required, although some consider retesting with changes in clinical symptoms.\u00a0If the results of the lupus anticoagulant are borderline, retesting after at least 1 week is suggested. [47]"}
{"id": "article-145910_25", "title": "Antiphospholipid Antibody Testing -- Testing Procedures", "content": "Many guidelines for lupus anticoagulant detection exist, including those from the International Society on Thrombosis and Haemostasis Scientific and Standardization Subcommittee (ISTH-SSC) in 2009. These guidelines are essential for\u00a0ensuring consistent testing and interpretation of lupus anticoagulant results,\u00a0particularly in less-than-ideal situations such as during new thrombotic events, including stroke, myocardial infarction, or deep venous thrombosis. [6] Lupus anticoagulant testing could be part of a thrombophilia workup or suspected catastrophic antiphospholipid syndrome, where the clinical decision to start anticoagulation is imperative. The guidelines also recommended testing of prothrombin time, APTT, and thrombin time before lupus anticoagulant testing in cases of unknown clinical and pharmacological history. [3]", "contents": "Antiphospholipid Antibody Testing -- Testing Procedures. Many guidelines for lupus anticoagulant detection exist, including those from the International Society on Thrombosis and Haemostasis Scientific and Standardization Subcommittee (ISTH-SSC) in 2009. These guidelines are essential for\u00a0ensuring consistent testing and interpretation of lupus anticoagulant results,\u00a0particularly in less-than-ideal situations such as during new thrombotic events, including stroke, myocardial infarction, or deep venous thrombosis. [6] Lupus anticoagulant testing could be part of a thrombophilia workup or suspected catastrophic antiphospholipid syndrome, where the clinical decision to start anticoagulation is imperative. The guidelines also recommended testing of prothrombin time, APTT, and thrombin time before lupus anticoagulant testing in cases of unknown clinical and pharmacological history. [3]"}
{"id": "article-145910_26", "title": "Antiphospholipid Antibody Testing -- Testing Procedures", "content": "British Committee for Standards in Haematology (BCSH) guidelines are less stringent compared to those of the ISTH. The Clinical and Laboratory Standards Institute (CLSI) also has established guidelines. [47]", "contents": "Antiphospholipid Antibody Testing -- Testing Procedures. British Committee for Standards in Haematology (BCSH) guidelines are less stringent compared to those of the ISTH. The Clinical and Laboratory Standards Institute (CLSI) also has established guidelines. [47]"}
{"id": "article-145910_27", "title": "Antiphospholipid Antibody Testing -- Testing Procedures", "content": "A prolonged thrombin time may indicate the presence of dabigatran or unfractionated heparin, which can affect lupus anticoagulant testing. Hence, the patient's report should include information about anticoagulation status. Low-molecular-weight heparin bridging is recommended if vitamin K antagonist anticoagulation cannot be withheld for 1 to 2 weeks before lupus anticoagulant testing. Once on low-molecular-weight heparin, lupus anticoagulant testing is performed at nadir levels of anticoagulation, at least 12 hours after the last dose or near the next dose, along with anti-Xa activity levels. In addition, lupus anticoagulant testing is performed after the incubation of plasma with heparinase. [6]", "contents": "Antiphospholipid Antibody Testing -- Testing Procedures. A prolonged thrombin time may indicate the presence of dabigatran or unfractionated heparin, which can affect lupus anticoagulant testing. Hence, the patient's report should include information about anticoagulation status. Low-molecular-weight heparin bridging is recommended if vitamin K antagonist anticoagulation cannot be withheld for 1 to 2 weeks before lupus anticoagulant testing. Once on low-molecular-weight heparin, lupus anticoagulant testing is performed at nadir levels of anticoagulation, at least 12 hours after the last dose or near the next dose, along with anti-Xa activity levels. In addition, lupus anticoagulant testing is performed after the incubation of plasma with heparinase. [6]"}
{"id": "article-145910_28", "title": "Antiphospholipid Antibody Testing -- Testing Procedures", "content": "On the other hand, direct oral anticoagulation should be held for at least 48\u00a0hours before lupus anticoagulant testing with longer patients with kidney disease.\u00a0Direct oral anticoagulants can prolong partial thromboplastin time. More specifically, dabigatran has a greater effect on APTT compared to rivaroxaban, whereas apixaban demonstrates the least effect. [3] [6] Anticoagulant neutralizers are also employed in some instances. [3] [4] [12] Antiphospholipid antibody testing, including lupus anticoagulant, also varies in pregnant women; therefore, negative testing does not exclude a diagnosis of antiphospholipid syndrome, especially with high clinical suspicion. Lupus anticoagulant testing is performed more reliably during the first trimester of pregnancy and should be repeated postpartum after at least 6 weeks, and preferably after 3 months postpartum. [6]", "contents": "Antiphospholipid Antibody Testing -- Testing Procedures. On the other hand, direct oral anticoagulation should be held for at least 48\u00a0hours before lupus anticoagulant testing with longer patients with kidney disease.\u00a0Direct oral anticoagulants can prolong partial thromboplastin time. More specifically, dabigatran has a greater effect on APTT compared to rivaroxaban, whereas apixaban demonstrates the least effect. [3] [6] Anticoagulant neutralizers are also employed in some instances. [3] [4] [12] Antiphospholipid antibody testing, including lupus anticoagulant, also varies in pregnant women; therefore, negative testing does not exclude a diagnosis of antiphospholipid syndrome, especially with high clinical suspicion. Lupus anticoagulant testing is performed more reliably during the first trimester of pregnancy and should be repeated postpartum after at least 6 weeks, and preferably after 3 months postpartum. [6]"}
{"id": "article-145910_29", "title": "Antiphospholipid Antibody Testing -- Testing Procedures", "content": "In addition to medications and pregnancy, acute thrombotic events can alter lupus anticoagulant testing. Acute thrombotic events can cause increased or\u00a0decreased\u00a0APTT with increased levels of factor VIII;\u00a0therefore,\u00a0patients should ideally be tested or retested when clinically stable and not in the setting of an acute event. [2] [3]", "contents": "Antiphospholipid Antibody Testing -- Testing Procedures. In addition to medications and pregnancy, acute thrombotic events can alter lupus anticoagulant testing. Acute thrombotic events can cause increased or\u00a0decreased\u00a0APTT with increased levels of factor VIII;\u00a0therefore,\u00a0patients should ideally be tested or retested when clinically stable and not in the setting of an acute event. [2] [3]"}
{"id": "article-145910_30", "title": "Antiphospholipid Antibody Testing -- Interfering Factors", "content": "Considering the variability of interpreting results and cutoff values, studies have assessed the practices of multiple clinical laboratories regarding lupus anticoagulant testing to ensure the accuracy of results, such as utilizing lyophilized plasmas containing anti-\u03b22GPIb and anticoagulated, lupus anticoagulant-negative plasma. [7] Reliability and uniformity in lupus anticoagulant\u00a0testing between different laboratories must be\u00a0evaluated consistently. As noted above, antiphospholipid syndrome\u2013related thrombotic complications are most highly associated with the presence of lupus anticoagulant, even in isolated lupus anticoagulant positivity; hence, accurate measurements are crucial. [2] [8]", "contents": "Antiphospholipid Antibody Testing -- Interfering Factors. Considering the variability of interpreting results and cutoff values, studies have assessed the practices of multiple clinical laboratories regarding lupus anticoagulant testing to ensure the accuracy of results, such as utilizing lyophilized plasmas containing anti-\u03b22GPIb and anticoagulated, lupus anticoagulant-negative plasma. [7] Reliability and uniformity in lupus anticoagulant\u00a0testing between different laboratories must be\u00a0evaluated consistently. As noted above, antiphospholipid syndrome\u2013related thrombotic complications are most highly associated with the presence of lupus anticoagulant, even in isolated lupus anticoagulant positivity; hence, accurate measurements are crucial. [2] [8]"}
{"id": "article-145910_31", "title": "Antiphospholipid Antibody Testing -- Results, Reporting, and Critical Findings", "content": "Guidelines for reporting and interpreting lupus anticoagulant testing results emphasize the importance of a sequential, multistep testing process, close collaboration between the laboratory and the clinician, and relating the results to the patient's clinical context and ongoing treatment. Results of lupus anticoagulant testing\u00a0should be reported as positive or negative, and comments such as borderline or dubious lupus anticoagulant are discouraged. Instead, in such cases, the recommendation should be to suggest retesting after 1 week or more without implying a positive or negative lupus anticoagulant.\u00a0In addition, the results should always be in conjunction with the results of anticardiolipin and anti-\u03b22GPIb to assess the risk profile, and local cutoff values must be reported along with an explanation of the results. [46]", "contents": "Antiphospholipid Antibody Testing -- Results, Reporting, and Critical Findings. Guidelines for reporting and interpreting lupus anticoagulant testing results emphasize the importance of a sequential, multistep testing process, close collaboration between the laboratory and the clinician, and relating the results to the patient's clinical context and ongoing treatment. Results of lupus anticoagulant testing\u00a0should be reported as positive or negative, and comments such as borderline or dubious lupus anticoagulant are discouraged. Instead, in such cases, the recommendation should be to suggest retesting after 1 week or more without implying a positive or negative lupus anticoagulant.\u00a0In addition, the results should always be in conjunction with the results of anticardiolipin and anti-\u03b22GPIb to assess the risk profile, and local cutoff values must be reported along with an explanation of the results. [46]"}
{"id": "article-145910_32", "title": "Antiphospholipid Antibody Testing -- Results, Reporting, and Critical Findings", "content": "The ISTH-SSC 2009 guidelines suggest using the 99th percentile for cutoff values, with a minimum of 40 donors required. However, accurately estimating the 99th percentile necessitates at least 120 healthy donors, and ideally 300 for statistical robustness. In-house cutoff values may significantly differ from manufacturer recommendations due to various factors. [48] Recent research advocates for nonparametric methods based on centiles for cutoff determination, as clotting times in lupus anticoagulant testing, do not follow a normal distribution. A study found a higher detection rate using the 95th centile compared to the 99th. However, removing outliers had minimal effects on inter-laboratory variability, suggesting that they are not the primary cause of variability. [47] Furthermore, the patient's anticoagulation status should be incorporated into the report, and a close interaction between the laboratory and the clinician is essential. [3]", "contents": "Antiphospholipid Antibody Testing -- Results, Reporting, and Critical Findings. The ISTH-SSC 2009 guidelines suggest using the 99th percentile for cutoff values, with a minimum of 40 donors required. However, accurately estimating the 99th percentile necessitates at least 120 healthy donors, and ideally 300 for statistical robustness. In-house cutoff values may significantly differ from manufacturer recommendations due to various factors. [48] Recent research advocates for nonparametric methods based on centiles for cutoff determination, as clotting times in lupus anticoagulant testing, do not follow a normal distribution. A study found a higher detection rate using the 95th centile compared to the 99th. However, removing outliers had minimal effects on inter-laboratory variability, suggesting that they are not the primary cause of variability. [47] Furthermore, the patient's anticoagulation status should be incorporated into the report, and a close interaction between the laboratory and the clinician is essential. [3]"}
{"id": "article-145910_33", "title": "Antiphospholipid Antibody Testing -- Clinical Significance", "content": "Triple positivity, indicating positive results for lupus anticoagulants, anticardiolipin antibodies, and anti-\u03b22GPIb, is linked to elevated risks of both initial and recurrent thrombotic events. This association is particularly notable in the presence of autoimmune diseases and when\u00a0the first thrombotic event occurs in asymptomatic carriers.\u00a0Insufficient diagnostic testing for antiphospholipid syndrome may result in an inaccurate diagnosis, potentially leading to serious consequences if timely interventions are not undertaken. [49] Several recent studies showed that rivaroxaban is ineffective for thrombosis prevention, leading to a recommendation for vitamin K antagonists over direct oral anticoagulants in the setting of triple positivity. [4] [15] [50]", "contents": "Antiphospholipid Antibody Testing -- Clinical Significance. Triple positivity, indicating positive results for lupus anticoagulants, anticardiolipin antibodies, and anti-\u03b22GPIb, is linked to elevated risks of both initial and recurrent thrombotic events. This association is particularly notable in the presence of autoimmune diseases and when\u00a0the first thrombotic event occurs in asymptomatic carriers.\u00a0Insufficient diagnostic testing for antiphospholipid syndrome may result in an inaccurate diagnosis, potentially leading to serious consequences if timely interventions are not undertaken. [49] Several recent studies showed that rivaroxaban is ineffective for thrombosis prevention, leading to a recommendation for vitamin K antagonists over direct oral anticoagulants in the setting of triple positivity. [4] [15] [50]"}
{"id": "article-145910_34", "title": "Antiphospholipid Antibody Testing -- Clinical Significance", "content": "Clinically, antiphospholipid syndrome is identified by thrombotic events or pregnancy-related complications. Antiphospholipid syndrome\u00a0is categorized as primary when not linked to other autoimmune diseases and as secondary antiphospholipid syndrome when associated with systemic autoimmune conditions such as systemic lupus erythematosus, rheumatoid arthritis, dermatomyositis, systemic sclerosis, and Sj\u00f6gren's syndrome. [51]", "contents": "Antiphospholipid Antibody Testing -- Clinical Significance. Clinically, antiphospholipid syndrome is identified by thrombotic events or pregnancy-related complications. Antiphospholipid syndrome\u00a0is categorized as primary when not linked to other autoimmune diseases and as secondary antiphospholipid syndrome when associated with systemic autoimmune conditions such as systemic lupus erythematosus, rheumatoid arthritis, dermatomyositis, systemic sclerosis, and Sj\u00f6gren's syndrome. [51]"}
{"id": "article-145910_35", "title": "Antiphospholipid Antibody Testing -- Clinical Significance", "content": "Antiphospholipid syndrome is associated with high morbidity rates, including cardiovascular events, such as myocardial infarction or cardiac emboli; recurrent miscarriages; intrauterine growth restriction; and venous thrombosis. Other multiorgan\u00a0systemic effects can be cutaneous, renal, neurologic, and hematologic involvement, including skin ulcers, epilepsy, or autoimmune hemolytic anemia. See StatPearls' companion reference, \" Antiphospholipid Syndrome ,\" for further information.", "contents": "Antiphospholipid Antibody Testing -- Clinical Significance. Antiphospholipid syndrome is associated with high morbidity rates, including cardiovascular events, such as myocardial infarction or cardiac emboli; recurrent miscarriages; intrauterine growth restriction; and venous thrombosis. Other multiorgan\u00a0systemic effects can be cutaneous, renal, neurologic, and hematologic involvement, including skin ulcers, epilepsy, or autoimmune hemolytic anemia. See StatPearls' companion reference, \" Antiphospholipid Syndrome ,\" for further information."}
{"id": "article-145910_36", "title": "Antiphospholipid Antibody Testing -- Clinical Significance", "content": "A rare but\u00a0dreaded life-threatening form of antiphospholipid syndrome is called catastrophic antiphospholipid syndrome. [52] This syndrome\u00a0is diagnosed by acute clinical manifestations of widespread multiorgan thrombosis developing in less than\u00a01 week, is evidenced by the\u00a0presence of antiphospholipid antibodies, at least 3-organ involvement, and confirmed by histopathologic occlusion of small vessels. Catastrophic antiphospholipid syndrome is associated with a high mortality rate of 30% to 50% regardless of treatment. [53]", "contents": "Antiphospholipid Antibody Testing -- Clinical Significance. A rare but\u00a0dreaded life-threatening form of antiphospholipid syndrome is called catastrophic antiphospholipid syndrome. [52] This syndrome\u00a0is diagnosed by acute clinical manifestations of widespread multiorgan thrombosis developing in less than\u00a01 week, is evidenced by the\u00a0presence of antiphospholipid antibodies, at least 3-organ involvement, and confirmed by histopathologic occlusion of small vessels. Catastrophic antiphospholipid syndrome is associated with a high mortality rate of 30% to 50% regardless of treatment. [53]"}
{"id": "article-145910_37", "title": "Antiphospholipid Antibody Testing -- Clinical Significance", "content": "In terms of other clinical scenarios involving lupus anticoagulant, a retrospective analysis studied the possible confounding effects of lupus anticoagulants in patients who received extracorporeal membrane oxygenation while on anticoagulation. [54] The analysis found that lupus anticoagulant-positive\u00a0patients did not exhibit a greater risk for developing thromboembolic complications compared to lupus anticoagulant-negative patients, but patients with lupus anticoagulants required a longer duration for extracorporeal membrane oxygenation treatment. Nevertheless, the\u00a0correlation of this outcome cannot be confirmed due to the direct effect of lupus anticoagulant or\u00a0merely the severity of the course of disease among these patients. Interestingly,\u00a0 lupus anticoagulants were also positive for patients with viral respiratory infections in this study. However, retesting after 1 to 6 months showed negative lupus anticoagulant, implying a transient presence in viral respiratory infections. [55]", "contents": "Antiphospholipid Antibody Testing -- Clinical Significance. In terms of other clinical scenarios involving lupus anticoagulant, a retrospective analysis studied the possible confounding effects of lupus anticoagulants in patients who received extracorporeal membrane oxygenation while on anticoagulation. [54] The analysis found that lupus anticoagulant-positive\u00a0patients did not exhibit a greater risk for developing thromboembolic complications compared to lupus anticoagulant-negative patients, but patients with lupus anticoagulants required a longer duration for extracorporeal membrane oxygenation treatment. Nevertheless, the\u00a0correlation of this outcome cannot be confirmed due to the direct effect of lupus anticoagulant or\u00a0merely the severity of the course of disease among these patients. Interestingly,\u00a0 lupus anticoagulants were also positive for patients with viral respiratory infections in this study. However, retesting after 1 to 6 months showed negative lupus anticoagulant, implying a transient presence in viral respiratory infections. [55]"}
{"id": "article-145910_38", "title": "Antiphospholipid Antibody Testing -- Clinical Significance", "content": "In another study, lupus anticoagulant was observed to be positive among patients with SARS-CoV-2 with prolonged APTT. About 90% were positive for lupus anticoagulant, and most of these patients were also associated with factor XII deficiency. However, it is unclear if any association occurs between the presence of lupus anticoagulant and COVID-19 thrombosis. [56] [57]", "contents": "Antiphospholipid Antibody Testing -- Clinical Significance. In another study, lupus anticoagulant was observed to be positive among patients with SARS-CoV-2 with prolonged APTT. About 90% were positive for lupus anticoagulant, and most of these patients were also associated with factor XII deficiency. However, it is unclear if any association occurs between the presence of lupus anticoagulant and COVID-19 thrombosis. [56] [57]"}
{"id": "article-145910_39", "title": "Antiphospholipid Antibody Testing -- Quality Control and Lab Safety", "content": "A quality management system in a clinical laboratory is essential for ensuring the accuracy and reliability of test results, which directly impact patient care and diagnosis. This system\u00a0involves established procedures for every testing step, from sample collection to result interpretation, to minimize the risk of errors and inconsistencies. Regular calibration and maintenance of equipment are also crucial, as they produce reliable results and reduce the chance of technical errors. [58] Key strategies for establishing a quality management system in a laboratory setting encompass organizational structuring, personnel training, equipment calibration and maintenance, method validation, quality control (QC) measures, and maintaining satisfactory customer communication. [59]", "contents": "Antiphospholipid Antibody Testing -- Quality Control and Lab Safety. A quality management system in a clinical laboratory is essential for ensuring the accuracy and reliability of test results, which directly impact patient care and diagnosis. This system\u00a0involves established procedures for every testing step, from sample collection to result interpretation, to minimize the risk of errors and inconsistencies. Regular calibration and maintenance of equipment are also crucial, as they produce reliable results and reduce the chance of technical errors. [58] Key strategies for establishing a quality management system in a laboratory setting encompass organizational structuring, personnel training, equipment calibration and maintenance, method validation, quality control (QC) measures, and maintaining satisfactory customer communication. [59]"}
{"id": "article-145910_40", "title": "Antiphospholipid Antibody Testing -- Quality Control and Lab Safety", "content": "QC is an integral part of a quality management system in a clinical laboratory. QC includes both internal and external components. Internal QC includes control procedures performed within a laboratory using surrogate samples intended to simulate clinical samples from patients to calibrate the machinery. [60] The QC samples are measured at intervals along with patient samples. Correlation with expected target values for the QC samples allows the laboratory to verify that a measurement procedure is working correctly and that the results for patient samples are reliable. [61] [62]", "contents": "Antiphospholipid Antibody Testing -- Quality Control and Lab Safety. QC is an integral part of a quality management system in a clinical laboratory. QC includes both internal and external components. Internal QC includes control procedures performed within a laboratory using surrogate samples intended to simulate clinical samples from patients to calibrate the machinery. [60] The QC samples are measured at intervals along with patient samples. Correlation with expected target values for the QC samples allows the laboratory to verify that a measurement procedure is working correctly and that the results for patient samples are reliable. [61] [62]"}
{"id": "article-145910_41", "title": "Antiphospholipid Antibody Testing -- Quality Control and Lab Safety", "content": "External QC, also called external quality assessment (EQA) or proficiency testing (PT),\u00a0is a process that allows laboratories to assess the reliability and accuracy of their testing. EQA/PT providers circulate a set of test samples among a group of laboratories. Each laboratory measures the EQA/PT samples as patient samples and reports the results to the EQA/PT provider for evaluation. [63] The EQA/PT provider assigns a target value to determine whether the results obtained by an individual laboratory consistently agree with the target values for acceptable measurement procedure performance. [64]", "contents": "Antiphospholipid Antibody Testing -- Quality Control and Lab Safety. External QC, also called external quality assessment (EQA) or proficiency testing (PT),\u00a0is a process that allows laboratories to assess the reliability and accuracy of their testing. EQA/PT providers circulate a set of test samples among a group of laboratories. Each laboratory measures the EQA/PT samples as patient samples and reports the results to the EQA/PT provider for evaluation. [63] The EQA/PT provider assigns a target value to determine whether the results obtained by an individual laboratory consistently agree with the target values for acceptable measurement procedure performance. [64]"}
{"id": "article-145910_42", "title": "Antiphospholipid Antibody Testing -- Quality Control and Lab Safety", "content": "All personnel must undergo comprehensive training\u00a0in safety protocols, hazard awareness, and emergency procedures. The use of appropriate personal protective equipment, such as gloves, lab coats, eye protection, and respiratory masks, is essential based on the specific hazards involved. Hazardous waste must be segregated, labeled, and disposed of in compliance with regulations. A well-defined emergency plan, coupled with easily accessible safety equipment, is critical for handling accidents or spills. Prompt reporting of safety incidents ensures thorough investigation and corrective actions. In a clinical laboratory, safety is a collective responsibility.\u00a0Adhering to protocols and fostering a safety culture protect staff well-being and enhance the precision and reliability of results, contributing to improved patient care. [65] [66]", "contents": "Antiphospholipid Antibody Testing -- Quality Control and Lab Safety. All personnel must undergo comprehensive training\u00a0in safety protocols, hazard awareness, and emergency procedures. The use of appropriate personal protective equipment, such as gloves, lab coats, eye protection, and respiratory masks, is essential based on the specific hazards involved. Hazardous waste must be segregated, labeled, and disposed of in compliance with regulations. A well-defined emergency plan, coupled with easily accessible safety equipment, is critical for handling accidents or spills. Prompt reporting of safety incidents ensures thorough investigation and corrective actions. In a clinical laboratory, safety is a collective responsibility.\u00a0Adhering to protocols and fostering a safety culture protect staff well-being and enhance the precision and reliability of results, contributing to improved patient care. [65] [66]"}
{"id": "article-145910_43", "title": "Antiphospholipid Antibody Testing -- Enhancing Healthcare Team Outcomes", "content": "The importance of\u00a0diagnostic testing for antiphospholipid antibodies requires multi-specialty participation and interprofessional management, starting with primary care providers and moving to inpatient and emergency settings. Appropriate referrals to rheumatologists and hematologists in the setting of connective tissue disease and thrombotic events should be performed promptly.", "contents": "Antiphospholipid Antibody Testing -- Enhancing Healthcare Team Outcomes. The importance of\u00a0diagnostic testing for antiphospholipid antibodies requires multi-specialty participation and interprofessional management, starting with primary care providers and moving to inpatient and emergency settings. Appropriate referrals to rheumatologists and hematologists in the setting of connective tissue disease and thrombotic events should be performed promptly."}
{"id": "article-145910_44", "title": "Antiphospholipid Antibody Testing -- Enhancing Healthcare Team Outcomes", "content": "Depending on the affected organs, specialists such as neurologists, nephrologists, obstetricians, gynecologists, and cardiologists are crucial to ensure a comprehensive approach to patient care and mitigate the risk of potential catastrophic events associated with the syndrome. The accuracy of laboratory technician reports depends on appropriate, close communication\u00a0between healthcare professionals, nurses, pharmacists, and laboratory staff in the presence of ongoing anticoagulation and other external factors. An interdisciplinary approach is essential to properly interpret results for overall management and determine the patient's clinical treatment and prognosis.", "contents": "Antiphospholipid Antibody Testing -- Enhancing Healthcare Team Outcomes. Depending on the affected organs, specialists such as neurologists, nephrologists, obstetricians, gynecologists, and cardiologists are crucial to ensure a comprehensive approach to patient care and mitigate the risk of potential catastrophic events associated with the syndrome. The accuracy of laboratory technician reports depends on appropriate, close communication\u00a0between healthcare professionals, nurses, pharmacists, and laboratory staff in the presence of ongoing anticoagulation and other external factors. An interdisciplinary approach is essential to properly interpret results for overall management and determine the patient's clinical treatment and prognosis."}
{"id": "article-145910_45", "title": "Antiphospholipid Antibody Testing -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Antiphospholipid Antibody Testing -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}